  but is not 
entitled to any remuneration in that capacity . 
 The remuneration report for the financial year 202 3 prepared by the Board ahead of the AGM 
2024 was approved at the AGM 2024. 
 
Key Developments 2024 
 The CEO , Fredrik Rågmark, summarizes the company’s overall performance in his statement 
on pages 7-8 of the Annual Report 2024. 
 
The Company’s remuneration guidelines: scope, purpose and deviations 
 Under the Remuneration Guidelines, remuneration of executive management shall be on 
market terms and may consist of the following components: fixed cash salary, variable cash remuneration, pension benefits and other benefits. The variable cash remuneration shall be linked to predetermined and measurable criteria which can be financial or non- financial. They 
may also be individualized, quantitative or qualitative objectives. The criteria shall be designed so as to contribute to the C ompany’s business strategy and long- term interest s, including its 
sustainability, by fer the 
executive management a competitive total remuneration. The total remuneration of the CEO 
during 2024 has complied with the R emuneration Guidelines. 
 
The CEO does not participate in the C ompany’s short -term annual incentive plan (STI) and the 
CEO does not receive any other short -term variable remuneration for 202 4. 
 
The CEO participates in all six Plans . The performance period has ended and vesting has 
occurred in 2024 under the Plan 2019 . By the end of 2024 , the performance period is still 
running under the respective five other Plan s (Plans 2020- 2024 ) and vesting has not yet 
occurred under any of th ose five Plans. 
 
Comparative information on the change of remuneration and C ompany performance 
 
The table below shows comparative information on the change of remuneration and Company 
performance for the financial year s 2020 , 2021, 2022, 2023 and 2024 .

Medicover AB (Publ) | P.O. Box 5 283 | SE-102 46 Stockholm | Visiting address: Riddargatan 12A | Swe iddargatan 12A | Sweden 
5 (5) 
 
Table 3 – Change of remuneration and company performance over the last five reported financial years (RFY) (EUR)(1) 
Annual change RFY-3 vs RFY -4 RFY-2 vs RFY -3 RFY-1 vs RFY -2 RFY vs RFY -1 RFY 202 4 
Director’s remuneration 
CEO remuneration +57,172 ( +6.3%) +2,344,357 (+242.2%) +448,562 (+13.5%) -916,178 ( -24.4%) 2,844,756(2) 
Company’s performance 
Group EBIT(3) (operating profit) +98,057,403 ( +159.8%) -104,229,690 ( -65.4%)(6) +6,208,100 (+11.3%) +8,967,041 (+14 .6%) 70,351,215 
Group EBITDA(4) +112,896,783 ( +71.7%) -53,356,125 ( -19.7%)(6) +26,732,537 (+12.3%) +41,116,248 (+16 .9%) 284,908,468 
Average remuneration on a full -time equivalent basis of employees 
Employees of the Company(5) +8,767 (+7.4%) -15,585 ( -12.2%) +25,976 (+23.2%) +20,655 (+15.0 %) 158,578 
 
(1) Amounts paid in SEK but stated in EUR have been calculated on the basis of an exchange rate of EUR/S EK 11.431 (Medi cover’s YTD average rate). 
(2) Total remuneration of the  remuneration of the CEO as set out in column 5 of Table 1 above. 
(3) Earnings before interest and tax. 
(4) Earnings before interest, other financial income/(expense), tax, amortisation, depreciation and impairment, other income/(costs) and share of profit/(loss) of associates. 
(5) Excluding members of the group executive management. The renumerations consists of base salary / fees, other benefits, variable renumeration, extraordinary items 
and pension expense, which is equal as the renumeration to CEO (Table 1). The average renumeration has been calculated by dividing the total renumeration with the 
average number of full -time employees in the Company, excluding the group executive management . 
(6) EBIT and EBITDA for the financial year 2022 have been restated for IFRS 17 compared to the remuneration report 2022. 
 
___________ 
 
Stockholm in March 2025 
Medicover AB (publ) 
The board of directors